Capula Management’s Harmony Biosciences HRMY Stock Holding History

Capula Management’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,610	Closed	-$860K	–	807
2022 Q4	$860K	Buy	+15,610	New	+$858K	0.01%	490

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capula Management's HRMY Position: Q1 2023 in Review

Capula Management sold out of Harmony Biosciences (HRMY) in Q1 2023, closing a stake of 15,610 shares — an estimated $860K sold.

Capula Management first reported a position in HRMY in Q4 2022 and held it in 1 quarter. The position peaked at $860K in Q4 2022. 217 funds tracked by Wall St. Rank hold HRMY as of Q1 2023.

Capula Management reported no remaining Harmony Biosciences position as of Q1 2023 after selling out during the quarter.
Capula Management sold 15,610 Harmony Biosciences shares in Q1 2023, an estimated $860K.
Capula Management first reported a position in Harmony Biosciences in Q4 2022 and held it in 1 quarter.
Capula Management's Harmony Biosciences position peaked at $860K in Q4 2022.
217 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2023.

Based on Capula Management's 13F filing for Q1 2023, filed 10 May 2023.